Table 2 Therapeutic suggestions using the Connectivity Map
Pharmaceutical perturbagen | Connectivity score | Description |
|---|---|---|
Hydrocortisone | -0.97 | Alimentary tract and metabolism (Aid in fat, protein and carbohydrate metabolism) |
Fulvestrant * | -0.952 | Estrogen receptor antagonist |
Gliclazide | -0.934 | Potent antiatherogenic effect in type 2 diabetes |
Deoxycortone | -0.917 | Corticosteroids for systemic use |
Sirolimus | -0.909 | Antineoplastic and immunomodulating agents |
Glimepiride | -0.905 | Sulfonylurea anti-diabetic drug |
Repaglinide | -0.895 | Treatment of type II diabetes |
Methotrexate * | -0.89 | Treatment of a number of cancers including breast |
Letrozole * | -0.882 | Non-steroidal aromatase inhibitor for the treatment of hormonally-responsive breast cancer after surgery |
Glipizide | -0.878 | Anti-diabetic drug from the sulfonylurea class |
Doxorubicin * | -0.868 | Treatment of a number of cancers including breast |
Glibenclamide | -0.867 | Antidiabetic drug in a class of medications known as sulfonylureas |
Tamoxifen * | -0.759 | Antagonist of the estrogen receptor in breast tissue |